Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

nosed in the U.S. annually, with the number increasing over the past 20-30 years. Carcinoid tumors that metastasize to the liver have a poor prognosis. Traditionally, chemotherapy relieves symptoms in less than 30% of cases of metastatic carcinoid tumors, usually for less than 1 year. Carcinoid tumors typically produce a condition called "carcinoid syndrome" which is caused by the release of hormones by the tumors into the blood stream. The symptoms vary depending on which hormones are released by the tumors, but typically include diarrhea, facial flushing, wheezing, abdominal pain and valvular heart disease.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  RT Oncology Services Corporation today announced that ... board of directors. Mr. Mundie is currently senior advisor ... on strategic projects within the company and on technology ... and strategy officer. Mike Martin ... "Craig is a visionary technology executive. His appointment is ...
(Date:7/23/2014)... BOHEMIA, N.Y. , July 23, 2014 /PRNewswire-iReach/ -- Top ... of GPM Pediatrics offers his feedback on article, which discusses ... Photo - http://photos.prnewswire.com/prnh/20140722/129440 According to ... of accidental injury and death among American children aged 1 ... inches of water." One expert in the article ...
(Date:7/23/2014)... , July 23, 2014  Mezzion Pharma Co. Ltd., ... evaluate the use of udenafil to treat adolescents who ... heart defects. The clinical program will follow protocols developed ... Pediatric Heart Network (PHN), a multi-center clinical research network ... (NHLBI) of the National Institutes of Health (NIH). ...
Breaking Medicine Technology:Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3Premier Staten Island Pediatrician Dr. Michael Gabriel Comments On Article Discussing Pool Safety Tips for Parents 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... Medical, Inc. (OTCBB: AEMD) announced today that its wholly ... ability of its Enzyme Linked Lectin Specific Assay (ELLSA) ... immunodeficiency virus (HIV), tuberculosis (TB), and various forms of ... July 2010, ESI disclosed that it filed a patent ...
... WARSAW, Ind., April 12, 2011 Zimmer Holdings, Inc. (NYSE: ... quarter 2011 sales and earnings conference call will be broadcast ... 8:00 a.m. Eastern Time.  A news release detailing the quarterly ... the morning of the conference call. The ...
Cached Medicine Technology:Aethlon Medical Announces Multi-Target Exosome Assay Validation 2Aethlon Medical Announces Multi-Target Exosome Assay Validation 3Aethlon Medical Announces Multi-Target Exosome Assay Validation 4Aethlon Medical Announces Multi-Target Exosome Assay Validation 5Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results 2
(Date:7/24/2014)... The Arm Lift, also known as brachioplasty, ... skin from the upper arms to create a more toned, ... arm can become lax and may begin to sag, resulting ... the appearance of sagging upper arms, and seek treatment to ... is now offering brachioplasty to tighten and improve the ...
(Date:7/24/2014)... The Republic of Tea, leading purveyor of premium teas, is ... celebrate “The Hundred-Foot Journey,” a new major motion picture produced ... journey begins in the moment when you bravely drop what ... is far out of your comfort zone. It is a ... the course of your life for the better. , ...
(Date:7/24/2014)... Jose, California (PRWEB) July 24, 2014 ... for sugar alcohols, commonly known as food polyols, is ... confectionery sectors. Rising incidence of obesity, growing awareness ... aging population vulnerable to diabetes are some of the ... With growing number of scientific studies validating the health ...
(Date:7/24/2014)... 24, 2014 Freeslate, Inc ... solutions for biopharmaceutical development, today announced its feature ... Formulations” by Jim Kling. Topics of this ... formulations and how automation can help address many ... formulations have been a growing focus of pharmaceutical ...
(Date:7/24/2014)... Imbue Partners is pleased to announce ... the National Women Business Owners Corporation ( NWBOC ). ... , Located near Boston, MA, Imbue Partners is ... growth through strategic planning, organizational competencies, and enabling processes. ... through teams, tools, and technologies for all phases of ...
Breaking Medicine News(10 mins):Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Freeslate Featured in BioProcess International Article Discussing Challenges and Solutions to Highly Concentrated Protein Formulations 2Health News:Freeslate Featured in BioProcess International Article Discussing Challenges and Solutions to Highly Concentrated Protein Formulations 3Health News:Imbue Partners Certified as Woman-Owned Small Business 2
... the first long-term randomized trial of a chemopreventive agent for ... cancer in the drug-treated group may be attributable to shrinkage ... The study of the Prostate Cancer Prevention Trial, led by ... Gann, is published in the Sept. 12 issue of the ...
... Providers, SEATTLE, Sept. 12 , News Facts -- ... concerns and interests to the 2008 presidential candidates ... online physician community. -- The initiative is enabling U.S. licensed ... via individual web-based videos. Experts from a ...
... Wrinkles, HIGHLANDS, N.J., Sept. 12 Fifty really ... men in their 40s and 50s look better than,their ... can look incredibly sexy at any age. So ... keep the,attention of handsome himbos and beautiful babes? Biocap, ...
... Corporation,(Nasdaq: KNSY ) today announced that it will ... 30, 2007 at 7:00 A.M. Eastern Time on,Friday, October ... be hosting a teleconference,discussing the earnings results on Friday, ... participate in the teleconference call, dial 1-651-291-5254. The,teleconference call ...
... billion dollars. , But an unhealthy kidney costs moreabout ... associate professor in the division of nephrology and hypertension ... about $17 billion a year to care for patients ... currently over 320,000 people undergoing hemodialysis in the United ...
... Centers Head and Neck Cancer Center is teaming up ... cancer. The clinical alliance between Mount Sinai and ENT ... allergy and audiology practice in the tri-state area, together ... quality care, cancer screening and advanced surgical options for ...
Cached Medicine News:Health News:Shrinkage of prostate led to overestimation of cancer risk in trial 2Health News:U.S. Physicians Question Presidential Candidates 2Health News:Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser 2Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Clinical trials present better alternatives for dialysis patients 2Health News:Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: